Fjarde AP Fonden Fourth Swedish National Pension Fund lessened its position in CVS Health Co. (NYSE:CVS - Free Report) by 5.0% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 303,519 shares of the pharmacy operator's stock after selling 15,900 shares during the period. Fjarde AP Fonden Fourth Swedish National Pension Fund's holdings in CVS Health were worth $13,625,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors have also recently bought and sold shares of the company. MidAtlantic Capital Management Inc. acquired a new position in CVS Health during the 3rd quarter worth $25,000. Ridgewood Investments LLC lifted its holdings in CVS Health by 255.7% in the fourth quarter. Ridgewood Investments LLC now owns 626 shares of the pharmacy operator's stock worth $28,000 after purchasing an additional 450 shares during the period. Stonebridge Financial Group LLC bought a new position in CVS Health in the 4th quarter valued at about $28,000. Legacy Investment Solutions LLC acquired a new position in CVS Health during the 3rd quarter valued at about $31,000. Finally, Reston Wealth Management LLC bought a new stake in shares of CVS Health during the 3rd quarter worth about $32,000. 80.66% of the stock is owned by institutional investors and hedge funds.
CVS Health Stock Up 1.1 %
NYSE:CVS traded up $0.68 during trading hours on Thursday, hitting $64.54. 8,275,092 shares of the stock traded hands, compared to its average volume of 12,605,323. The firm has a market cap of $81.37 billion, a price-to-earnings ratio of 17.63, a PEG ratio of 0.98 and a beta of 0.61. The firm has a 50 day moving average price of $53.48 and a 200 day moving average price of $56.34. The company has a current ratio of 0.81, a quick ratio of 0.60 and a debt-to-equity ratio of 0.80. CVS Health Co. has a fifty-two week low of $43.56 and a fifty-two week high of $80.75.
CVS Health (NYSE:CVS - Get Free Report) last announced its quarterly earnings data on Wednesday, February 12th. The pharmacy operator reported $1.19 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.89 by $0.30. CVS Health had a return on equity of 9.11% and a net margin of 1.24%. Equities research analysts anticipate that CVS Health Co. will post 5.89 earnings per share for the current year.
CVS Health Announces Dividend
The business also recently disclosed a quarterly dividend, which was paid on Monday, February 3rd. Shareholders of record on Thursday, January 23rd were paid a $0.665 dividend. The ex-dividend date of this dividend was Thursday, January 23rd. This represents a $2.66 annualized dividend and a yield of 4.12%. CVS Health's dividend payout ratio is presently 72.68%.
Insiders Place Their Bets
In related news, Director Michael F. Mahoney purchased 30,000 shares of the company's stock in a transaction dated Tuesday, February 18th. The shares were acquired at an average cost of $66.70 per share, with a total value of $2,001,000.00. Following the completion of the purchase, the director now owns 39,356 shares of the company's stock, valued at $2,625,045.20. The trade was a 320.65 % increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 0.24% of the company's stock.
Wall Street Analyst Weigh In
CVS has been the subject of several recent analyst reports. JPMorgan Chase & Co. increased their price objective on shares of CVS Health from $80.00 to $81.00 and gave the company an "overweight" rating in a report on Tuesday, February 18th. Leerink Partnrs upgraded CVS Health from a "hold" rating to a "strong-buy" rating in a research report on Wednesday, February 12th. Truist Financial boosted their price objective on CVS Health from $60.00 to $76.00 and gave the stock a "buy" rating in a research note on Thursday, February 13th. StockNews.com raised CVS Health from a "sell" rating to a "hold" rating in a report on Thursday, February 13th. Finally, Evercore ISI boosted their price target on shares of CVS Health from $60.00 to $65.00 and gave the stock an "outperform" rating in a research report on Monday, January 27th. Four equities research analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $70.00.
Read Our Latest Analysis on CVS Health
CVS Health Company Profile
(
Free Report)
CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.
See Also
Before you consider CVS Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CVS Health wasn't on the list.
While CVS Health currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
